In head and neck cancer patients undergoing RT and randomised to therapy with epoetin beta or placebo, locoregional control and survival were significantly worse in the EPO-treated group, although anemia was corrected in these patients (Henke et al, 2003). This evidence concerns the gene EPO and head and neck cancer.